Twist Bioscience CORP Form 4 insider transactions

A Twist Bioscience executive sold shares to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily Leproust sold 2,216 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Twist Bioscience executive sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Twist Bioscience CEO Emily Leproust reported the acquisition of 95,350 shares of common stock and various transactions related to employee stock options.

Twist Bioscience's President and COO, Patrick John Finn, was granted 53,634 restricted stock units on December 4, 2024.

Twist Bioscience's Chief Financial Officer, Adam Laponis, acquired 26,745 restricted stock units on December 4, 2024.

Paula Green, SVP of Human Resources at Twist Bioscience, acquired 20,428 shares of common stock through the vesting of a restricted stock unit award.

Dennis Cho, a Senior Vice President at Twist Bioscience, acquired 22,824 shares of common stock through the vesting of restricted stock units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience, received 8,438 restricted stock units (RSUs) on December 4, 2024.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 789 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Twist Bioscience executive sold 1,811 shares to cover tax obligations related to vesting performance stock units.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 4,160 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Twist Bioscience CEO Emily M. Leproust sold 14,334 shares to cover tax obligations related to vesting Performance Stock Units.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 1,448 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 5,519 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 6,239 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Director Robert Chess of Twist Bioscience Corp. executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

A Twist Bioscience executive, Dennis Cho, sold 1,507 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience's President and COO, Patrick John Finn, sold 10,340 shares of common stock to cover tax obligations related to vesting restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,347 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily Leproust sold 7,968 shares of common stock to cover tax obligations related to vesting restricted stock units.

Emily Leproust, CEO of Twist Bioscience, sold 14,334 shares of common stock on November 6, 2024, to cover tax obligations related to vesting performance stock units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold 1,448 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 5,519 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Adam Laponis, CFO of Twist Bioscience, sold 4,160 shares of common stock on November 6, 2024, to satisfy tax withholding obligations related to vesting Performance Stock Units.

Patrick John Finn, COO of Twist Bioscience, sold 6,239 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Dennis Cho, a Twist Bioscience executive, sold 1,811 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, reports the acquisition and disposition of company stock to cover tax obligations related to vesting restricted stock units.

Dennis Cho, a Senior Vice President at Twist Bioscience, reports the acquisition and disposal of company stock related to the vesting of performance stock units (PSUs) and subsequent tax obligations.

CEO Emily Leproust reports acquisition of shares through performance stock units and subsequent sale to cover tax obligations.